NDC 43825-200

Terlivaz

Terlipressin

Terlivaz is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Mallinckrodt Hospital Products Inc.. The primary component is Terlipressin.

Product ID43825-200_08efe631-e704-4997-a4f2-ac2131c051f1
NDC43825-200
Product TypeHuman Prescription Drug
Proprietary NameTerlivaz
Generic NameTerlipressin
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2022-09-14
Marketing CategoryNDA /
Application NumberNDA022231
Labeler NameMallinckrodt Hospital Products Inc.
Substance NameTERLIPRESSIN
Active Ingredient Strength1 mg/5mL
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 43825-200-01

1 VIAL, SINGLE-DOSE in 1 CARTON (43825-200-01) > 5 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2022-09-14
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Terlivaz]

Mark Image

Registration | Serial
Company
Trademark
Application Date
TERLIVAZ
TERLIVAZ
98802165 not registered Live/Pending
Mallinckrodt Pharmaceuticals Ireland Limited
2024-10-15
TERLIVAZ
TERLIVAZ
97051486 not registered Live/Pending
Mallinckrodt Hospital Products IP Limited
2021-09-29
TERLIVAZ
TERLIVAZ
85876469 4720688 Live/Registered
Ikaria Therapeutics LLC
2013-03-14

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.